FDA clearance is part of Company's three-part strategy to change the business paradigm for the molecular diagnostic industry
ArcherDX and Illumina will work together to develop and bring multiple Archer® NGS-based IVD assays through the FDA approval process
A database of 29,000 unique biomarkers (for more than 1800 human diseases), which are manually extracted from US patent/WO (PCT) publications and PubMed abstracts.
